MedTrace Logo

Body Composition and Fatty Liver Disease

NCT05695118 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-08-18

No results posted yet for this study

Summary

This study investigates relationship between fatty liver prognosis and body composition analysis result based on non-contrast low dose CT in patients with fatty liver disease.

Conditions

Interventions

DIAGNOSTIC_TEST

Non-contrast low-dose abdomen CT

target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.

DIAGNOSTIC_TEST

Fibroscan

Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.

DIAGNOSTIC_TEST

bioelectrical impedance analysis (BIA)

BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jeong Min Lee, MD · Professor

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-10
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05695118 on ClinicalTrials.gov